


PHARMACEUTICAL 2021

Immunome Inc. Rank 73 of 402







RealRate

Immunome Inc. Rank 73 of 402

The relative strengths and weaknesses of Immunome Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Immunome Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 176% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	42,894
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,038
Liabilities, Non-Current	134
Other Assets	100
Other Compr. Net Income	0
Other Expenses	5,576
Other Liabilities	8.0
Other Net Income	0
Other Revenues	0
Property and Equipment	1,531
Research and Development	7,486
Selling, General and Administrative Expense	4,775

Output Variable	Value in 1000 USD
Assets	44,525
Liabilities	3,180
Expenses	17,837
Revenues	0
Stockholders Equity	41,345
Net Income	-17,837
Comprehensive Net Income	-17,837
Economic Capital Ratio	223%

